INCOMING! New PepMix Peptide Pools for M. Tuberculosis!

Published on 15/05/2025 T-cell receptor-engineered T-cell therapy (TCR-T) is rapidly gaining momentum in the field of cancer immunotherapy. Unlike CAR-T cells, which recognize surface antigens, TCR-T cells can detect and eliminate cancer cells based on intracellular tumor-associated antigens presented by MHC molecules, offering broader therapeutic opportunities across solid and hematologic malignancies. A recent comprehensive review (Zhang et al., 2023) highlights the 16 major cancer targets currently pursued in TCR-T clinical trials. JPT is proud to support researchers in this exciting field by offering PepMix™ Peptide Pools for 15 of these 16 critical targets — and a partial PepMix™ for the remaining one (EGFRvIII). Main TCR-T Targets Available as PepMix™ Peptide Pools: AFP (Alpha-fetoprotein) EGFRvIII (partially available as ErbB2-ICD and ErbB2-ECD) EBV (Epstein-Barr Virus) HA-1 HBV (Hepatitis B Virus) HPV (Human Papillomavirus) KK-LC-1 KRAS (mutated) MAGE-A1 MAGE-A3 MAGE-A4 MAGE-A10 MART-1 Mesothelin NY-ESO-1 WT1 Check all our tumor-associated antigen peptide pools and our more than 1500 individual epitope peptides. Why Choose PepMix™ Peptide Pools for TCR-T Research? Comprehensive Antigen Coverage: Each PepMix™ consists of overlapping peptides that span the full protein sequence, ensuring maximal coverage of known and novel epitopes — ideal for discovery, monitoring, and functional assays. High Quality and Batch Consistency: Our optimized synthesis and stringent QC processes guarantee high purity, reproducibility, and biological performance you can trust for clinical research. Experience with Difficult Sequences: Hydrophobic and aggregation-prone sequences? No problem. JPT’s proven expertise ensures even challenging targets are fully represented in your peptide pool. Immediate Availability: More than 450 different catalog PepMix™ peptide pools are available from stock — enabling faster project initiation and smoother workflows. In case we do not have you antigen, contact us! We can provide it to you as a custom PepMix™ Peptide Pool. Accelerate Your TCR-T Research PepMix™ Peptide Pools are widely used for: Screening TCRs for target specificity Monitoring T-cell responses post-infusion Identifying immunodominant epitopes Supporting preclinical and translational studies Advance your TCR-T programs with reliable tools trusted by researchers worldwide and learn more about The World of PepMix™ or contact us!

PepMix™ Peptide Pools are instrumental in cancer immunotherapy, particularly for exploring tumor-associated antigens and improving T cell responses. JPT’s PepMix™ Peptide Pools support the development of novel cancer vaccines and therapeutic strategies targeting tumor-specific markers. Below, you will find key studies referencing JPT’s PepMix™ Peptide Pools in research.